- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01200979
Assessment of Alterations in Immune Function During Pregnancy and Post Parturition
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
Traditionally, it has been suggested that pregnancy causes an immunosuppressive state that would facilitate fetal tolerance and result in an increased susceptibility to infection. Although the suppression has been characterized as a global T-cell defect, the observation that the increase in susceptibility is restricted only to specific intracellular bacteria and viruses is consistent with a down regulation of only certain components of the innate immune system. Progress in the treatment and management of infections during pregnancy will require further understanding of the changes to the immune system that occur during pregnancy. It is hypothesized that there is a fundamental down-regulation in the innate immune system that occurs during pregnancy and remains until delivery and that changes in serum cytokines influence na(SqrRoot) ve CD4 differentiation to different subpopulations. To that end, this study will evaluate blood samples drawn from pregnant women during early, mid, and late pregnancy and post-partum for changes in the innate immune system and compare them to data on a similar cohort of women of childbearing age from an existing database of healthy, non-pregnant women. Changes in the cytokine profile, gene expression by microarray, and in the lymphocyte and natural killer (NK) cell populations will be identified. We may perform neutrophil analysis. We will evaluate toll-like receptors functionality, and any changes in PBMC throughout pregnancy.
We also plan to evaluate serum cytokine panels, PBMC by flow cytometry, and PBMC for microarray of gene expression, before and after administration of the influenza vaccine in up to 20 of the 40 pregnant subjects. Antibody levels will be measured as well.
A comparison of any observed changes will be made with those previously reported for in vitro and in vivo studies.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
Maryland
-
Bethesda, Maryland, Stati Uniti, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
- INCLUSION CRITERIA:
All pregnant study subjects must:
- Be between the ages of 18-45 years old.
- Have a positive pregnancy test (urine).
- Be of an estimated gestational age of between 10 and 20 weeks either by ultrasound or LMP.
- Have an identified primary care provider for the pregnancy.
- Be willing to sign the collaborative study consent form from CHI.
- Be willing to have samples collected and stored for future research and immunological studies
- Be willing to sign the collaborative study consent form for normal volunteers from CHI
Up to twenty pregnant subjects who agree to receive the seasonal influenza vaccine must:
- Have no history of allergic reaction to the vaccine or its contents
- Not have received the vaccine from other providers this flu season
- Agree to have an additional 20cc of blood drawn at both Day +1 and Day +7 post-vaccine for immune analysis.
EXCLUSION CRITIERIA:
A subject will be excluded if she:
- Has an identified underlying chronic medical condition that may adversely affect the immune system (e.g., autoimmune, HIV, or hematologic) or the need for immunomodulating medications (e.g., oral steroids) within 30 days prior to conception for a suspected immune disorder. Oral steroid use for any other reason must have been discontinued for at least 30 days prior to participation.
- Is found to have a Hemoglobin reading of less than 8g/dL.
- Has any other medical condition which, in the opinion of the Principal Investigator, poses an unacceptable risk to the subject s participation in the study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: Caso di controllo
- Prospettive temporali: Prospettiva
Coorti e interventi
Gruppo / Coorte |
---|
pregnant flu vaccinated
pregnant women that choose to receive the seasonal flu vaccine
|
pregnant non-flu vaccinated
pregnant women that do not receive the flu vaccine
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Changes in lymphocyte and NK cell populations during pregnancy compared to non-pregnant control samples.
Lasso di tempo: 1st, 2nd, and 3rd trimesters and postpartum and postpartum
|
Changes in lymphocyte and NK cell populations during pregnancy compared to non- pregnant control samples.
[Time Frame: 1st, 2nd, and 3rd trimesters and postpartum and postpartum]
|
1st, 2nd, and 3rd trimesters and postpartum and postpartum
|
Changes in Cytokine profiles during pregnancy
Lasso di tempo: 1st, 2nd, and 3rd trimesters and postpartum and postpartum
|
Changes in Cytokine profiles during pregnancy compared to non-pregnant control samples
|
1st, 2nd, and 3rd trimesters and postpartum and postpartum
|
Functionality of Toll-like receptors and changes in gene expression
Lasso di tempo: 1st, 2nd, and 3rd trimesters and postpartum and postpartum
|
Functionality of Toll-like receptors and changes in gene expression during pregnancy during pregnancy compared to non-pregnant control samples [Time Frame: 1st, 2nd, and 3rd trimesters and postpartum]
|
1st, 2nd, and 3rd trimesters and postpartum and postpartum
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Functionality of Toll-like receptors and changes in gene expression
Lasso di tempo: Before and after the administration of the influenza vaccine in a subset of pregnant women
|
Functionality of Toll-like receptors and changes in gene expression during pregnancy during pregnancy compared to non-pregnant control samples, in a subset of pregnant women [Time Frame: Before and after the administration of the influenza vaccine in a subset of pregnant women]
|
Before and after the administration of the influenza vaccine in a subset of pregnant women
|
Changes in lymphocyte and INK cell populations
Lasso di tempo: Before and after the administration of the influenza vaccine in a subset of pregnant women
|
Changes in lymphocyte and INK cell populations during pregnancy compared to non-pregnant control samples, in a subset of pregnant women [Time Frame: Before and after the administration of the influenza vaccine in a subset of pregnant women]
|
Before and after the administration of the influenza vaccine in a subset of pregnant women
|
Changes in Cytokine profiles
Lasso di tempo: Before and after the administration of the influenza vaccine in a subset of pregnant women
|
Changes in Cytokine profiles during pregnancy compared to non-pregnant control samples, in a subset of pregnant women [Time Frame: Before and after the administration of the influenza vaccine in a subset of pregnant women]
|
Before and after the administration of the influenza vaccine in a subset of pregnant women
|
Collaboratori e investigatori
Pubblicazioni e link utili
Pubblicazioni generali
- Pejcic-Karapetrovic B, Gurnani K, Russell MS, Finlay BB, Sad S, Krishnan L. Pregnancy impairs the innate immune resistance to Salmonella typhimurium leading to rapid fatal infection. J Immunol. 2007 Nov 1;179(9):6088-96. doi: 10.4049/jimmunol.179.9.6088.
- Luppi P. How immune mechanisms are affected by pregnancy. Vaccine. 2003 Jul 28;21(24):3352-7. doi: 10.1016/s0264-410x(03)00331-1.
- Zhao J, Lei Z, Liu Y, Li B, Zhang L, Fang H, Song C, Wang X, Zhang GM, Feng ZH, Huang B. Human pregnancy up-regulates Tim-3 in innate immune cells for systemic immunity. J Immunol. 2009 May 15;182(10):6618-24. doi: 10.4049/jimmunol.0803876.
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- 100205
- 10-I-0205
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .